- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02368912
A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects
A Double Blind, Randomized, Placebo-controlled, Ascending Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1707 in Healthy Young and Elderly Male Subjects and in Healthy Pre-menopausal Female Subjects Including an Open-label Comparison of Pharmacokinetics Under Fasted and Fed Conditions in Healthy Young Male Subjects
This study consists of four parts:
Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy young male subjects to evaluate the safety, tolerability pharmacokinetics (PK) and effect on certain hormones and if possible to determine the highest well-tolerated dose of ASP1707 in healthy young male subjects under fasted conditions.
Part 2 is an open label, randomized crossover, single dose study to determine the effect of food on the pharmacokinetics of ASP1707and effect on certain hormones in healthy young male subjects.
Part 3 is a randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PK) of ASP1707 in healthy elderly men and healthy premenopausal females, and to determine the effect on certain hormones in males. Age and gender is also evaluated.
Part 4 is a randomized, double-blind, placebo-controlled, parallel, multiple dose study to evaluate the safety, tolerability and PK of ASP1707, and its effect on certain hormones in healthy pre-menopausal female subjects.
연구 개요
상태
개입 / 치료
- 의약품: ASP1707 single dose of dose levels 1 -7
- 의약품: Placebo single dose of dose levels 1-7
- 의약품: ASP1707 single dose fasted
- 의약품: ASP1707 single dose fed
- 의약품: ASP1707 multiple dose of dose levels 1-4
- 의약품: Placebo multiple dose of dose levels 1-4
- 의약품: ASP1707 multiple dose of dose levels 1-2
- 의약품: Placebo multiple dose of dose levels 1-2
- 의약품: ASP1707 parallel multiple dose of dose levels 1-3
- 의약품: Placebo parallel multiple dose
상세 설명
Part 1 comprises 7 dose groups of 8 healthy young male subjects. ASP1707 or matching placebo ( 3 to 1 ratio) is given as a single dose under fasted conditions.
The first group receives the lowest dose while the last group receives the highest dose.
Part 2 (Food-Effect) The group consists of 12 healthy young male subjects who receive two separate doses of ASP1707 under fasted or fed conditions. Half of the subjects are dosed first under fasted condition and half of them had first an FDA high-fat breakfast. Subjects receive the alternate treatment on the second occasion. Dosing is separated by at least 7 days or 7 times t1/2 (terminal elimination half-life) as assessed from Part 1.
Part 3 Comprises 4 dose groups of 12 healthy elderly men each, and two groups of 12 healthy premenopausal women. The latter are dosed ASP1707 or placebo in parallel to the 4 male groups. Subjects are fasted or fed depending on observations from Part 2.
Dose levels are defined after evaluating interim safety, tolerability and PK and PD results from Part 1. A lower maximum dose is used in women than in men, based on preclinical data. Dose escalation in the men is independent from dose escalation in the women. Women and men receive once-daily dosing;
Part 4 includes 4 groups, 1 placebo and 3 for ASP1707, each with 9 pre-menopausal women. Subjects in each dose group receive a fixed daily dose. Subjects are domiciled for various intervals during each of 3 menstrual cycles. Dosing occurs for 21 Days during the subjects' second menstrual cycle of the study (Day 1 of Period 2); fasted or fed depending on observations from Part 2.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Paris, 프랑스, 75015
- SGS Life Science Services, Aster
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Parts 1 & 2:
- Healthy young male subject aged 18 to 45 years inclusive
- Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
- Male subjects must be non-fertile, or must practice an adequate contraceptive method to prevent pregnancies.
Part 3:
- Healthy elderly male subject aged 55 years or older, or healthy pre-menopausal female subject aged 18 to 45 inclusive.
- Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
- Male subject must be non-fertile, or must practice adequate contraceptive methods.
- Female subjects must be of non-child bearing potential, i.e. surgically sterilized or practice adequate (double barrier) non-hormonal contraceptive methods.
Part 4:
- Healthy pre-menopausal female subject aged 18 to 45 inclusive.
- Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
- Female subjects must be of non-child bearing potential, i.e. surgically sterilized or practice adequate contraceptive methods.
- Females having a regular menstruation cycle with a duration between 25 up to 30 days.
Exclusion Criteria:
Parts 1 & 2:
- Male subjects with out-of-range Testosterone levels in serum at screening.
- Subjects with any history of cancer.
- Any of the liver function tests (i.e. ALT and AST) above the upper limit of normal.
- A QTc interval of > 430 ms after repeated measurements.
- Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
- Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
Part 3:
- Pregnancy within 6 months before screening assessment or breast feeding 3 months before screening.
- Male subjects with out-of-range T levels in serum at screening.
- Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
Part 4:
- Pregnancy within 6 months before screening assessment or breast feeding 3 months before screening.
- Use of any hormonal interfering contraceptives in the 3 months before admission (for 3 consecutive menstruation cycles) OR any evidence of unovulatory menstrual cycles.
- Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: 1. Single ascending dose (SAD), ASP1707 dose levels 1-7
healthy young male
|
Oral, dose escalation
|
실험적: 2. Single ascending dose (SAD), placebo dose levels 1-7
healthy young male
|
Oral, dose escalation, healthy young male
|
실험적: 3. Food effect (FE), ASP1707 fasted
Fasted healthy young male
|
Oral, healthy young male
|
실험적: 4. Food effect (FE), ASP1707 fed
Fed healthy young male
|
Oral, healthy young male
|
실험적: 5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4
healthy elderly male
|
Oral, multiple dose escalation, healthy elderly male
|
실험적: 6. Multiple ascending dose (MAD), Placebo, dose levels 1-4
healthy elderly male
|
Oral, multiple dose escalation, healthy elderly male
|
실험적: 7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2
healthy pre-menopausal female
|
Oral, multiple dose escalation, healthy pre-menopausal female
|
실험적: 8. Multiple ascending dose (MAD), Placebo dose levels 1-2
healthy pre-menopausal female
|
Oral, multiple dose escalation, healthy pre-menopausal female
|
실험적: 9. Parallel multiple dose, ASP1707 dose levels 1-3
healthy pre-menopausal female
|
Oral, multiple dose, healthy pre-menopausal female
|
실험적: 10. Parallel multiple dose, Placebo
healthy pre-menopausal female
|
Oral, dose escalation, healthy pre-menopausal female
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Safety assessed by nature, frequency and severity of adverse events
기간: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Respectively Part 1 and Part 3
|
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Safety assessed by physical examination
기간: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Respectively Part 1 and Part 3
|
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Safety assessed by vital signs
기간: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Respectively Part 1 and Part 3. Vital signs include blood pressure and pulse.
|
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Safety assessed by safety laboratory tests
기간: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Respectively Part 1 and Part 3, Biochemistry, hematology, and urinalysis
|
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Safety assessed by 12 lead electrocardiogram (ECG)
기간: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Respectively Part 1 and Part 3
|
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
|
Safety assessed by continuous cardiac monitoring (Holter)
기간: Days -1 and 21
|
Part 3
|
Days -1 and 21
|
Pharmacokinetics (PK) of ASP1707 measured by area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by area under the plasma concentration-time curve (AUC) to time from the time of dosing to the last measurable concentration (AUClast) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by time to reach quantifiable concentrations (tlag) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by time to attain maximum concentration (tmax) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by Cmax in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by terminal elimination half-life (t1/2) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by apparent volume of distribution (Vz/F) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by apparent clearance (CL/F) in plasma
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by amount excreted unchanged into urine (Ae) from time of dosing until last measurable concentration (Aelast) in urine
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by Ae extrapolated to time = infinity (Aeinf) in urine
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by Ae in % up to the collection time of the last measurable concentration (Aelast%) in urine
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by Ae in % extrapolated to time infinity (Aeinf%) in urine
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
PK of ASP1707 measured by renal clearance (CLR) in urine
기간: Pre-dose (Day 1) to Day 5
|
Part 2
|
Pre-dose (Day 1) to Day 5
|
Pharmacodynamics (PD) of ASP1707 measured by Cmax in plasma
기간: Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
|
Part 4, period 1, 2 and 3. Estradiol (E2), Follicle-stimulating hormone (FSH) and Luteinizing Hormone (LH) levels
|
Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
|
PD of ASP1707 measured by tmax in plasma
기간: Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
|
Part 4, period 1, 2 and 3. E2, FSH and LH levels
|
Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
|
PD of ASP1707 measured by average concentration (Cavg, day 7-15) in plasma
기간: Pre-dose to Day 26
|
Part 4, period 1, 2 and 3. E2, FSH and LH levels
|
Pre-dose to Day 26
|
PD of ASP1707 measured by average concentration (Cavg, day 5-19) in plasma
기간: Pre-dose to Day 26
|
Part 4, period 3. E2, FSH and LH levels
|
Pre-dose to Day 26
|
PD of ASP1707 measured by average concentration (Cavg, day 23-26) in plasma
기간: Pre-dose to Day 26
|
Part 4, period 2. E2, FSH and LH levels
|
Pre-dose to Day 26
|
PD of ASP1707 - maximal duration within therapeutic range
기간: Pre-dose to Day 26
|
Part 4, period 2. E2 levels
|
Pre-dose to Day 26
|
PD of ASP1707 - total duration within therapeutic range (20-50 pg/mL)
기간: Pre-dose to Day 26
|
Part 4, period 2. E2 levels
|
Pre-dose to Day 26
|
PD of ASP1707 - Time of onset therapeutic range
기간: Pre-dose to Day 26
|
Part 4, period 2. E2 levels
|
Pre-dose to Day 26
|
PD of ASP1707 - Time of offset therapeutic range
기간: Pre-dose to Day 26
|
Part 4, period 2. E2 levels
|
Pre-dose to Day 26
|
PD of ASP1707 - Time of start menstruation after last dose of study drug
기간: Pre-dose to Day 26
|
Part 4, period 3
|
Pre-dose to Day 26
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
PK profile of ASP1707 in plasma and urine for Part 1
기간: Pre-dose (Day 1) to Day 5
|
AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR
|
Pre-dose (Day 1) to Day 5
|
Safety profile assessed by nature, frequency and severity of adverse events, physical examination, vital signs, safety laboratory tests and 12 lead ECG
기간: Screening to End of Study Visit (ESV) (Up to 31 days and up to 62 days)
|
Respectively Part 2 and Part 4
|
Screening to End of Study Visit (ESV) (Up to 31 days and up to 62 days)
|
PD profile of ASP1707 for Part 1 and Part 2
기간: Pre-dose (Day 1) to Day 12-19
|
Testosterone (T), LH and FSH levels: Cmin, tmin, maximal %Reduction and T only: Number and percentage of subjects with T castration level (= T < 0.5 ng/mL) after single dose, Time of onset of T < 0.5 ng/mL after single dose, Duration of T <0.5 ng/mL after single dose
|
Pre-dose (Day 1) to Day 12-19
|
PD profile of ASP1707 for Part 3
기간: Pre-dose (Day 1) to Day 39
|
T, LH and FSH levels: Cmin, tmin, maximal %Reduction T only: Number and percentage of subjects with T < 0.5 ng/mL at any time post-first dose, Number and percentage of subjects with T < 0.5 ng/mL after last dose, Number of subjects reaching T<0.5 ng/mL for ≥14 days, Day of onset of T < 0.5 ng/mL after multiple doses of ASP1707 (T < 0.5 ng/mL for the first time), Time of onset of T < 0.5 ng/mL after first dose, Duration of T < 0.5 ng/mL after single dose and during multiple dosing, Total duration, Maximal duration:Time from last dose to return to baseline levels for T, LH and FSH, Duration of T < 0.5 ng/mL after last dose
|
Pre-dose (Day 1) to Day 39
|
PK profile of ASP1707 in plasma and urine for Part 3
기간: Pre-dose (Day 1) to Day 25
|
AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR, Ctrough, AUC during the time interval between consecutive dosing (AUCtau), Accumulation Ratio (Rac), Peak Trough Ratio (PTR), Ae during the time interval between consecutive dosing (Aetau), Aetau as percentage of total dose (Aetau%), Ae during the time interval between consecutive dosing (AUCtau), (AUC0-24h), Ae0-24h, Ae0-24h%
|
Pre-dose (Day 1) to Day 25
|
PK profile of ASP1707 in plasma and urine for Part 4
기간: Pre-dose (Day 23) to Day 25
|
AUCtau, tmax, Cmax, t1/2, Vz/F, CL/F, CLR, Ctrough, PTR, Aetau, Aetau%,
|
Pre-dose (Day 23) to Day 25
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 1707-CL-0001
- 2010-018292-21 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
ASP1707의 약동학에 대한 임상 시험
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)완전한
-
Queens College, The City University of New York모병
-
Swansea University완전한A Bite of ACT' (BOA) 수용전념치료 온라인 심리교육 과정 | 대기자 명단 제어영국
-
Hôpital Léon Bérard완전한
-
Scripps Translational Science Institute완전한
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
University Hospital Inselspital, BerneDeka Medical, Inc.모집하지 않고 적극적으로
-
University of Pennsylvania완전한Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410의 주진단 또는 이차진단 코드가 있는 환자(5번째 숫자가 2인 경우 제외)미국
-
Catherine Vandepitte, M.D.Pacira Pharmaceuticals, Inc완전한
-
Jerry Vockley, MD, PhDUltragenyx Pharmaceutical Inc더 이상 사용할 수 없음바르트 증후군 | 미토콘드리아 삼중기능 단백질 결핍 | 초장쇄 acylCoA 탈수소효소(VLCAD) 결핍증 | 카르니틴 팔미토일전이효소 결핍(CPT1, CPT2) | 장쇄 하이드록시아실-CoA 탈수소효소 결핍증 | 글리코겐 저장 장애 | 피루브산 카르복실라제 결핍증 | ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of미국
ASP1707 single dose of dose levels 1 -7에 대한 임상 시험
-
Meissa Vaccines, Inc.모병
-
Merck Sharp & Dohme LLC완전한